Taking the extraction yield of Bletilla striata polysaccharide (BSP) as the index and taking the type of deep eutectic solvents (DESs), extraction time, extraction temperature, DES water content, and solid–liquid ratio as the investigation factors, single-factor and Box–Behnken response surface tests were carried out to optimize the extraction process of BSP. Thus, the antioxidant activity of BSP on DPPH radicals, ABTS radicals and ferric reducing antioxidant power were determined. The results showed that the most suitable deep eutectic solvent was DES-2, namely choline chloride-urea. The optimal extraction conditions for BSP were an extraction time of 47 min, extraction temperature of 78 °C, water content of 35%, and solid–liquid ratio of 1:25. Under this optimized condition, the extraction yield of BSP was able to reach (558.90 ± 8.83) mg/g, and recycling studies indicated the good cycle stability of the DES. Antioxidant results showed that BSP had superior antioxidant activity and had a dose–response relationship with drug concentration. Compared with Bletilla striata polysaccharide obtained via conventional hot water extraction (BSP-W), the extraction yield of BSP obtained through this method (BSP-2) increased by 36.77%, the scavenging activity of DPPH radicals increased by 24.99%, the scavenging activity of ABTS radicals increased by 41.16%, and the ferric reducing antioxidant power increased by 49.19%. Therefore, DESs as new green reagents and BSP extracted with DESs not only had a high yield but also had strong antioxidant activity.
This study investigated the pharmacological and pathological effects of aqueous mulberry leaf extract on type 1 diabetes mellitus mice induced with an intraperitoneal injection of streptozotocin (STZ). Diabetic mice were randomized into six groups: control (normal group), model, metformin-treated mice, and high-dose, medium-dose, and low-dose mulberry. The mulberry-treated mice were divided into high-, medium-, and low-dose groups based on the various doses of aqueous mulberry leaf extract during gavage. The efficacy of the six-week intervention was evaluated by measuring levels of fasting plasma glucose, alkaline phosphatase, alanine aminotransferase, aspartate transaminase, blood urea nitrogen, gamma-glutamyl transferase, glucose, high-density lipoprotein cholesterol, lactate dehydrogenase, and low-density lipoprotein cholesterol and recording body weight. Results revealed that mulberry leaf extract exhibited an ideal hypoglycemic effect, and the high-dose group was the most affected. Histology analysis, glycogen staining and apoptosis detection were used to study the extract’s effects on the liver, kidney, and pancreatic cells of diabetic mice, enabling the assessment of its effectiveness and complications on a clinical and theoretical basis. It was shown that a certain concentration of aqueous mulberry leaf extract repaired the islet cells of type 1 diabetes mellitus mice, promoting normal insulin secretion. Herein, it was confirmed that mulberry leaf could be used to develop new hypoglycemic drugs or functional health food with broad applicability.
Background: The short-term 0-1-2-months hepatitis B virus (HBV) vaccination schedule was previously proposed in the adult population; however, its long-term immune effect remains unclear. The present study was aimed to investigate 1) the 2-months and 2-year immune effect of HBV vaccination; and 2) compliance rate between 0-1-2-months and 0-1-6-months vaccination schedules in adults.Method: A total of 1281 subjects tested for HBsAg(-) and Hepatitis B surface antibody (anti-HBs)(-) were recruited. Participants from two distant counties were inoculated hepatitis B yeast vaccine for 10ug per dose each time, with 0-1-2-months (n=606) and 0-1-6-months (n=675) vaccination schedule, sequentially followed-up at two months and two years after the 3rd injection.Results: There was no statistical difference in anti-HBs seroconversion rate between 0-1-2-months and 0-1-6-months vaccination schedule at two months (91.96% vs 89.42%, p=0.229) and two years (81.06% vs. 77.14%, p=0.217). Quantitative anti-HBs level of 0-1-2-months vaccination schedule was not different with 0-1-6-months vaccination schedule at 2 months (anti-HBs1) (342.12 ± 378.42 m IU/ml vs. 392.38 ± 391.96 m IU/ml, p=0.062), but was higher at two years (anti-HBs2) (198.37 ± 286.44 m IU /ml vs. 155.65 ± 271.73 m IU /ml, p=0.048). By subgroup analysis, 0-1-2-months vaccination schedule showed better maintenance (p=0.041) and delayed reinforcement (p=0.019) in comparison to 0-1-6 vaccination schedule. The 0-1-2-months vaccination schedule also increased the 3rd-time injection completion rate (89.49% vs. 84.49%, p=0.010).Conclusion: the 0-1-2-months vaccination could obtain a similar short-term immune effect, but achieve a better long-term immune memory and a higher completion rate in the adult population.Trial registration: None
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.